Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 5Breast Diseases 4Thoracic Neoplasms 3Respiratory Tract Neoplasms 3Neoplasms 3Lung Diseases 3Bronchial Neoplasms 3Neoplasms, Glandular and Epithelial 2Neoplasms by Histologic Type 2Melanoma 2Kidney Neoplasms 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Respiratory Tract Diseases 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Mammary Neoplasms, Animal 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Bronchogenic 1Advanced Breast Cancer 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × entinostat × Clear all
NCT02915523 2024-01-10

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Syndax Pharmaceuticals

Phase 1/2 Completed
140 enrolled 25 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡